Summary & Overview
CPT 4187F: Disease Modifying Antirheumatic Drug Therapy
CPT code 4187F designates that a provider prescribes or dispenses a disease modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis. DMARDs alter the course of disease by suppressing the immune and inflammatory systems to reduce pain, inflammation, and joint damage. Nationally, use of this code signals active medical management of inflammatory arthritis and informs quality measurement and medication monitoring efforts.
Key payers commonly involved in coverage and claims processing include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. This publication outlines the clinical context for CPT code 4187F, typical settings where it is used, and the administrative considerations relevant to payers and providers.
Readers will learn the clinical purpose of the code, where and how it is typically reported (outpatient/rheumatology settings and outpatient infusion centers), and which national payers are relevant for claims and coverage. The report also summarizes what types of benchmarks and policy topics are typically associated with DMARD reporting—such as medication adherence tracking, prior authorization practices, and integration with quality measurement—while noting specific payer policies and detailed benchmark data are separate sections. Data not available in the input are identified where applicable.
Billing Code Overview
CPT code 4187F is reported when a provider prescribes or dispenses a disease modifying antirheumatic drug (DMARD) therapy for a patient. These medications are used to treat rheumatoid arthritis by suppressing the immune and inflammatory response to reduce pain and joint damage.
Service Type: Medication management and drug therapy provision
Typical Site of Service: Outpatient clinic, rheumatology office, or outpatient infusion/infusion center, where the provider prescribes or dispenses DMARDs or arranges outpatient administration.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with established rheumatoid arthritis who presents to a rheumatology clinic for initiation or continuation of disease-modifying antirheumatic drug therapy. The visit includes a focused history of disease activity, review of current and prior medications, screening for infection risk (including TB and hepatitis), baseline laboratory testing (CBC, CMP, CRP/ESR, hepatitis serologies), and counseling about medication risks and monitoring. The provider documents the decision to prescribe or dispense a disease-modifying antirheumatic drug (DMARD) such as methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or biologic agents (for example TNF inhibitors), and arranges appropriate monitoring and follow‑up. Typical workflow steps: pre-visit medication reconciliation, in-clinic assessment and consent, ordering baseline labs and vaccinations as indicated, electronic or pharmacy prescription/dispense action, and scheduling follow-up for monitoring and dose adjustments. Typical site of service: ambulatory rheumatology clinic, specialty infusion center (for infused biologics), or outpatient pharmacy dispensing at the clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when an E/M visit is performed the same day as prescribing/dispensing and meets E/M documentation requirements |